| Patient | Samuel Johnson |
|---|---|
| Date of birth | 1970-09-18 |
| Identifiers | MRN HR-EN008-SYN; SSN (made up) 000-08-7139 |
| Document date | 2026-06-22 |
| Author | Catriona Bell, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Eleven-week review of depression and tics. [S]
Mr. Johnson returns five weeks after sertraline was increased to 100 mg. He is writing most mornings again and dines with friends several times a week. He wakes less often in dread. He has mild night sweats and no other side effects. He has had six of eight sessions of behavioral therapy for tics and uses the competing response for the head-shaking tic in company; the clucking sounds are less frequent. There was no check two weeks after the dose increase. [S]
| Element | Detail |
|---|---|
| Sertraline | 100 mg daily for five weeks |
| Mood | PHQ-9 10 |
| Function | Writing most mornings; seeing friends |
| Tic therapy | Six of eight sessions |
| Side effects | Mild night sweats |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Mild night sweats; no fever or weight loss |
| Neurological | Positive | Tics less frequent |
| Psychiatric | Negative | Mood much better; no thoughts of suicide or self-harm |
3 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Sertraline 50 mg oral tablet, one tablet by mouth once daily | One tablet by mouth once daily in the morning | Oral route | 2026-04-06 to 2026-05-18 | completed | S |
| Sertraline 100 mg oral tablet, one tablet by mouth once daily | One tablet by mouth once daily in the morning | Oral route | 2026-05-18 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-06-22 | Body height | 183 | cm | S |
| 2026-06-22 | Body weight | 98.6 | kg | S |
| 2026-06-22 | Body mass index (BMI) [Ratio] | 29.4 | kg/m2 | S |
| 2026-06-22 | Systolic blood pressure | 124 | mm[Hg] | S |
| 2026-06-22 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-06-22 | Heart rate | 76 | /min | S |
| 2026-06-22 | Respiratory rate | 14 | /min | S |
| 2026-06-22 | Body temperature | 36.6 | Cel | S |
| 2026-06-22 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-06-22 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 10 | {score} | S |
Vital signs recorded on 2026-06-22; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 124/78, pulse 76 |
| Neurological | Fewer head-turning tics and sounds during the visit |
| Psychiatric | Brighter; humorous and engaged |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Major depressive disorder, recurrent, severe, without psychotic features: low mood, loss of interest, poor sleep, guilt, and withdrawal from company for about three months on a background of depression that never fully lifted after a severe episode last year; first episode at about twenty; synthetic modern episode linked to his documented melancholy | active | confirmed | F33.2 | S — Synthetic modern diagnosis by DSM-5 criteria; the record makes no claim about his real mental health. |
| Motor and vocal tics since childhood, with ritual counting and stepping behaviors, never formally diagnosed; neurology evaluation requested | resolved | confirmed | F95.9 | S — Synthetic presenting concern anchored to the documented tics; superseded by the diagnosis at the neurology consultation. |
| Tourette syndrome: multiple motor tics and vocal tics since childhood, with premonitory urges, brief suppressibility, and tic-related obsessive-compulsive symptoms (counting, evening-up, and threshold rituals); synthetic modern diagnosis by DSM-5 criteria at the neurology consultation, linked to the documented tics and to the retrospective diagnosis | active | confirmed | F95.2 | S — Synthetic modern diagnosis; the retrospective historical diagnosis is graded R and is not asserted as fact. |
| Blindness of the left eye since early childhood after scrofula (tuberculous cervical lymphadenitis), with old scars of the neck and face; right eye myopic, corrected to normal; synthetic modern coding linked to his documented loss of sight in one eye | active | confirmed | H54.42 | S — Synthetic modern coding; the source does not say which eye, so the left is a synthetic choice. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Depression measure (PHQ-9) | At baseline and at least monthly during acute treatment; every 2 to 4 weeks in continuation | Completed today | 10: response, not yet remission |
| Medication safety | Sertraline adherence and adverse effects | Every visit in the acute phase; reassess at 2 weeks after starting and after each dose change | Completed today | Mild night sweats; adherent |
| Medication safety | Reassessment two weeks after the sertraline dose increase | Two weeks after each dose change | Deferred | Protocol deviation: no check two weeks after the increase to 100 mg; the next contact was today, five weeks later. No harm resulted: no activation, no new suicidal thoughts, and PHQ-9 fell to 10. Corrective action: a nurse phone check two weeks after any future dose change |
| Survey | Suicide-risk review (PHQ-9 item 9 and structured questions since the last visit), safety plan, and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm |
| Referral | Psychotherapy (cognitive behavioral therapy with behavioral activation) | Offer to all with moderate or severe depression | Completed today | Ten sessions; now every two weeks |
| Survey | Anxiety measure (GAD-7) | At baseline and with PHQ-9 reviews | Up to date | 9 five weeks ago |
| Survey | Tic severity (Yale Global Tic Severity Scale, recorded in the note; no LOINC code is used) | At diagnosis and periodically to judge the need for and response to treatment | Completed today | Total tic score 26; impairment 10 |
| Referral | Comprehensive Behavioral Intervention for Tics | Offer as an initial treatment option | Completed today | Six of eight sessions |
| Medication safety | Tic-suppressing medication (alpha-2 agonist, aripiprazole, or other) | When tics cause impairment that behavioral therapy does not relieve | Not indicated | Not needed |
Goal progress:
Guideline basis: Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders (Pringsheim T, et al. Neurology 2019;92(19):896-906) (2019); VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)
Follow-up: Preventive visit in five weeks. Six-month review in the autumn. Next scheduled visit 2026-07-27: periodic adult preventive visit. [S]